Identification of Microorganisms Using Nucleic Acid Probes
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Texas Policy RPLAB063 alerts
Get alerted when Policy RPLAB063 changes without checking for updates manually.
Monitor payer policy activity
This reimbursement policy governs when nucleic acid identification tests using direct probes, amplified probes, or quantification may be reimbursable or are not reimbursable. It applies to providers submitting laboratory claims to Blue Cross Blue Shield of Texas, subject to applicable plan documents, provider contracts, coding rules, and claim edits.
Pneumocystis jirovecii amplified probe code 87594 and Rubeola virus amplified probe code 87638 were added as may be reimbursable.
Non-vaginal Candida species and Mycoplasma genitalium, along with their associated codes, were removed from the reimbursement table.
Direct probe testing for Chlamydia pneumoniae, Cytomegalovirus, Legionella pneumophila, Herpes-virus-6, and Mycoplasma pneumoniae changed from may be reimbursable to not reimbursable.
The simultaneous-ordering rule was revised to state that ordering amplified probe and quantification tests for the same organism in one encounter is not reimbursable.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.